The board of the new company, Resilience, includes a who’s who of former industry and government officials.
The furious race to develop a coronavirus vaccine played out against a presidential election, between a pharmaceutical giant and a biotech upstart, with the stakes as high as they could get.
Novartis has secured a global license to Mesoblast’s cell therapy remestemcel-L in the treatment of COVID-19. The deal lands Mesoblast $50 million upfront and the support of a partner that ...
AstraZeneca, with partner Oxford University, released preliminary data for its phase 3 Covid-19 Monday showing that the vaccine may be up to 90% effective.
By Peter Hébert
Biotech punches way above its weight-class, and that’s never been more apparent than in this pandemic and the race for a COVID vaccine. For those of us in biopharma, it feels like it’s a ...
The deal, which has Pfizer paying as much as $70 million, is the latest in a series of moves by big pharma companies to forge a stronger position in the world's second-largest drug market.
Big Pharma friend argenx has snapped up an FDA priority review voucher from Bayer for $98 million.